Chronimed to spin off diagnostics business:
This article was originally published in Clinica
Chronimed, a US patient management and supply service for people with chronic conditions, is to spin off its diagnostic products division into a separate company that will trade on the Nasdaq stock exchange. Minneapolis, Minnesota-based Chronimed will distribute shares as a tax-free dividend to shareholders. The decision comes after consultancy led by Paine-Webber identified the separate nature of the company's pharmacy and diagnostics businesses.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.